Director, Controller

About this role

<div class="content-intro"><p><strong>About us:</strong></p> <div> <p class="x_MsoNormal"><span data-olk-copy-source="MessageBody">Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.</span></p> </div> <div> <p class="x_MsoNormal">With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.</p> </div> <p> </p></div><p><strong><span data-contrast="auto">The role:</span></strong><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The Director, Controller is an experienced leader that will build and run the financial infrastructure of our fast-moving clinical-stage biotechnology company. Reporting to the VP of Finance, this individual will own day-to-day accounting operations and related internal controls, including month-end, quarter-end, and year-end close processes, as well as lead necessary system implementations to support the Company’s continued growth. This is a hands-on role that will collaborate with various internal and external partners, including non-finance operating teams.</span><span data-ccp-props="{}"> </span></p> <p> </p> <p><strong><span data-contrast="auto">Key responsibilities:</span></strong><span data-ccp-props="{}"> </span></p> <ul> <li data-leveltext="" data-font="Symbol" data-listid="1" data-list-defn-props="{"335552541":1,"335559685":720,"335559991":360,"469769226":"Symbol","469769242":[8226],"469777803":"left","469777804":"","469777815":"multilevel"}" data-aria-posinset="1" data-aria-level="1"><span data-contrast="none"><span data-ccp-parastyle="Aon Body Copy" data-ccp-parastyle-defn="{"ObjectId":"70f00212-7eaf-5bf1-af52-7de8fb010795|1","ClassId":1073872969,"Properties":[201342446,"1",201342447,"5",201342448,"1",201342449,"1",469777841,"Arial",469777842,"Times New Roman",469777843,"MS Mincho",469777844,"Arial",201341986,"1",469769226,"Arial,Times New Roman,MS Mincho",268442635,"20",469775450,"Aon Body Copy",201340122,"2",134234082,"true",134233614,"true",469778129,"AonBodyCopy",335572020,"1",335559740,"264",201341983,"0",335559739,"240",469777929,"Aon Body Copy Char",469778324,"Normal"]}" data-ccp-parastyle-linked-defn="{"ObjectId":"c2133bd1-b909-5928-b08c-fba783318264|1","ClassId":1073872969,"Properties":[201342446,"1",201342447,"5",201342448,"1",201342449,"1",469777841,"Arial",469777842,"Times New Roman",469777843,"MS Mincho",469777844,"Arial",201341986,"1",469769226,"Arial,Times New Roman,MS Mincho",268442635,"20",469775450,"Aon Body Copy Char",201340122,"1",134233614,"true",469778129,"AonBodyCopyChar",335572020,"1",134231262,"true",469777929,"Aon Body Copy",469778324,"Default Paragraph Font"]}">Own </span><span data-ccp-parastyle="Aon Body Copy">the </span><span data-ccp-parastyle="Aon Body Copy">monthly, quarterly, and annual close proces</span><span data-ccp-parastyle="Aon Body Copy">s</span><span data-ccp-parastyle="Aon Body Copy"> </span><span data-ccp-parastyle="Aon Body Copy">to ensure </span><span data-ccp-parastyle="Aon Body Copy">accurate</span><span data-ccp-parastyle="Aon Body Copy"> financial statements on a timeline that meets </span><span data-ccp-parastyle="Aon Body Copy">internal and external</span><span data-ccp-parastyle="Aon Body Copy"> reporting deadlines.</span></span><span…